Adina Soaita

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, William J. Sandborn, Geert D’Haens et al. · The Lancet · 2017 · 435 citations · Full text

Inflammation, Rheumatology, Placebo-controlled Phase 2 +8

Sensitivity of Amplitude-Integrated Electroencephalography for Neonatal Seizure Detection

Renée A. Shellhaas, Adina Soaita, Robert R. Clancy · PEDIATRICS · 2007 · 288 citations

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Brian G. Feagan, Julián Panés, Marc Ferrante et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 156 citations · Full text

Autoimmune Disease, Open-label Extension Study, Immunology +5

A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome

Richard P. Allen, Crystal Chen, Adina Soaita et al. · Sleep Medicine · 2010 · 99 citations

Translational Pharmacology, Medicine, Restless Legs +6

On the Limiting Behavior of the “Probability of Claiming Superiority” in a Bayesian Context

Morris L. Eaton, Robb J. Muirhead, Adina Soaita · Bayesian Analysis · 2013 · 19 citations · Full text